{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:51:20Z","timestamp":1787241080990,"version":"build-2736575974"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.pharmthera.2015.10.003","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T15:19:35Z","timestamp":1445613575000},"page":"44-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["TGF-\u03b2\/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?"],"prefix":"10.1016","volume":"156","author":[{"given":"Jos\u00e9 M.","family":"Mu\u00f1oz-F\u00e9lix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"L\u00f3pez-Novoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.10.003_bb0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.1996.297","article-title":"Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis","volume":"50","author":"Akagi","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.devcel.2008.06.013","article-title":"Crossveinless-2 Is a BMP feedback inhibitor that binds Chordin\/BMP to regulate Xenopus embryonic patterning","volume":"15","author":"Ambrosio","year":"2008","journal-title":"Dev Cell"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0015","doi-asserted-by":"crossref","first-page":"e54662","DOI":"10.1371\/journal.pone.0054662","article-title":"Urinary microRNA profiling in the nephropathy of type 1 diabetes","volume":"8","author":"Argyropoulos","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0344-0338(80)80051-3","article-title":"Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters","volume":"167","author":"Bader","year":"1980","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0025","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/jpet.103.055616","article-title":"Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity","volume":"307","author":"Baylis","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-13-1840","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer","volume":"20","author":"Bendell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1097\/01.ASN.0000074238.61967.B7","article-title":"Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat","volume":"14","author":"Benigni","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0040","doi-asserted-by":"crossref","first-page":"20656","DOI":"10.3390\/ijms151120656","article-title":"Potential roles of BMP9 in liver fibrosis","volume":"15","author":"Bi","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00018-011-0751-1","article-title":"BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain","volume":"69","author":"Bidart","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0050","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/01.ATV.0000225287.20034.2c","article-title":"Transforming growth factor-betas and vascular disorders","volume":"26","author":"Bobik","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0055","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semnephrol.2012.07.008","article-title":"Can we target tubular damage to prevent renal function decline in diabetes?","volume":"32","author":"Bonventre","year":"2012","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2010.120","article-title":"Renal fibrosis: novel insights into mechanisms and therapeutic targets","volume":"6","author":"Boor","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0065","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis","volume":"331","author":"Border","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/360361a0","article-title":"Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease","volume":"360","author":"Border","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ki.1992.83","article-title":"Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis","volume":"41","author":"Border","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1681\/ASN.2012101031","article-title":"TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis","volume":"24","author":"Borges","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0085","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1096\/fj.11-185017","article-title":"Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis","volume":"25","author":"Borgeson","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0090","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/bjs.6996","article-title":"Endoglin negatively regulates transforming growth factor beta1-induced profibrotic responses in intestinal fibroblasts","volume":"97","author":"Burke","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0110","doi-asserted-by":"crossref","first-page":"e106554","DOI":"10.1371\/journal.pone.0106554","article-title":"The AMPK agonist AICAR inhibits TGF-beta1 induced activation of kidney myofibroblasts","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0006-291X(02)02708-0","article-title":"Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db\/db mice","volume":"300","author":"Chen","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0105","doi-asserted-by":"crossref","first-page":"e83593","DOI":"10.1371\/journal.pone.0083593","article-title":"Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5\/6 nephrectomized rats","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0120","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1096\/fj.06-5898fje","article-title":"Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury","volume":"20","author":"Cheng","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0125","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/jcb.25150","article-title":"Growth hormone induces transforming growth factor-beta-induced protein in podocytes: implications for podocyte depletion and proteinuria","volume":"116","author":"Chitra","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1053\/hupa.2000.20373","article-title":"Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor","volume":"31","author":"Choi","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/mt.2012.251","article-title":"Smad7 suppresses renal fibrosis via altering expression of TGF-beta\/Smad3-regulated microRNAs","volume":"21","author":"Chung","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0145","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1681\/ASN.2010020134","article-title":"miR-192 mediates TGF-beta\/Smad3-driven renal fibrosis","volume":"21","author":"Chung","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fphys.2015.00050","article-title":"MicroRNAs in renal fibrosis","volume":"6","author":"Chung","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0095","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1242\/dev.01419","article-title":"A vertebrate crossveinless 2 homologue modulates BMP activity and neural crest cell migration","volume":"131","author":"Coles","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20091309","article-title":"Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis","volume":"207","author":"Cunha","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0160","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0165","doi-asserted-by":"crossref","first-page":"e1696","DOI":"10.1371\/journal.pntd.0001696","article-title":"Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease","volume":"6","author":"de Oliveira","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ajpath.2010.12.005","article-title":"Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis","volume":"178","author":"Dendooven","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0180","first-page":"275","article-title":"The TGF beta receptor endoglin in systemic sclerosis","volume":"19","author":"Dharmapatni","year":"2001","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0925-4439(02)00051-0","article-title":"Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis","volume":"1587","author":"Diez-Marques","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0195","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1681\/ASN.V7122495","article-title":"Molecular insights into renal interstitial fibrosis","volume":"7","author":"Eddy","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2005.06.023","article-title":"RNAi: the nuts and bolts of the RISC machine","volume":"122","author":"Filipowicz","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0205","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.joca.2010.09.002","article-title":"Endoglin differentially regulates TGF-beta-induced Smad2\/3 and Smad1\/5 signalling and its expression correlates with extracellular matrix production and cellular differentiation state in human chondrocytes","volume":"18","author":"Finnson","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0215","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.bbamcr.2013.07.008","article-title":"The small GTPase N-Ras regulates extracellular matrix synthesis, proliferation and migration in fibroblasts","volume":"1833","author":"Fuentes-Calvo","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.diabres.2007.08.009","article-title":"Ferulic acid prevents pathological and functional abnormalities of the kidney in Otsuka Long\u2013Evans Tokushima Fatty diabetic rats","volume":"79","author":"Fujita","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1523-1755.2004.00713.x","article-title":"Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells","volume":"66","author":"Gaedeke","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cytogfr.2005.09.005","article-title":"Role of anti-TGF-beta antibodies in the treatment of renal injury","volume":"17","author":"Gagliardini","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0235","doi-asserted-by":"crossref","first-page":"F481","DOI":"10.1152\/ajprenal.00496.2012","article-title":"Transforming growth factor-beta1 receptor inhibition preserves glomerulotubular integrity during ureteral obstruction in adults but worsens injury in neonatal mice","volume":"304","author":"Galarreta","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0240","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2010.88","article-title":"An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease","volume":"77","author":"Garcia-Sanchez","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0245","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1021\/jm0509905","article-title":"Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor","volume":"49","author":"Gellibert","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0250","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.20104","article-title":"Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma","volume":"50","author":"Ghosh","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0255","doi-asserted-by":"crossref","first-page":"e58014","DOI":"10.1371\/journal.pone.0058014","article-title":"Increased circulating miR-21 levels are associated with kidney fibrosis","volume":"8","author":"Glowacki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0260","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bbadis.2013.05.016","article-title":"The ALK-1\/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?","volume":"1832","author":"Gonzalez-Nunez","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0265","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","article-title":"Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta\/ALK5 signaling","volume":"12","author":"Goumans","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0270","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/emboj\/21.7.1743","article-title":"Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors","volume":"21","author":"Goumans","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.2009.498","article-title":"Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice","volume":"77","author":"Grande","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0280","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2174\/092986708785132889","article-title":"Therapeutical relevance of MAP-kinase inhibitors in renal diseases: current knowledge and future clinical perspectives","volume":"15","author":"Grande","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2009.74","article-title":"Fibroblast activation and myofibroblast generation in obstructive nephropathy","volume":"5","author":"Grande","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-9255-7-19","article-title":"Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy","volume":"7","author":"Grande","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0295","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nm.3901","article-title":"Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease","volume":"21","author":"Grande","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0300","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1681\/ASN.2010070722","article-title":"Circulating bone morphogenetic protein 1\u20133 isoform increases renal fibrosis","volume":"22","author":"Grgurevic","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0305","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0925-4773(00)00524-4","article-title":"Bambi is coexpressed with Bmp-4 during mouse embryogenesis","volume":"100","author":"Grotewold","year":"2001","journal-title":"Mech Dev"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0310","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1073\/pnas.0807200106","article-title":"A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions","volume":"105","author":"Grutter","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0315","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/jpet.104.082099","article-title":"Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis","volume":"313","author":"Grygielko","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0320","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/labinvest.2013.4","article-title":"Blockade of Smad signaling by 3\u2032-deoxyadenosine: a mechanism for its anti-fibrotic potential","volume":"93","author":"Gu","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0325","doi-asserted-by":"crossref","first-page":"e39406","DOI":"10.1371\/journal.pone.0039406","article-title":"BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFbeta signaling","volume":"7","author":"Guillot","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0330","first-page":"1337","article-title":"CD105 inhibits transforming growth factor-beta-Smad3 signalling","volume":"24","author":"Guo","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0335","first-page":"F199","article-title":"TGF-beta stimulates rat mesangial cell proliferation in culture: role of PDGF beta-receptor expression","volume":"264","author":"Haberstroh","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0340","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1096\/fj.03-0037fje","article-title":"Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells","volume":"17","author":"Hayashida","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0345","doi-asserted-by":"crossref","DOI":"10.1007\/s12015-015-9615-7","article-title":"Peroxisome proliferator-activated receptor gamma promotes mesenchymal stem cells to express connexin43 via the inhibition of TGF-beta1\/Smads signaling in a rat model of myocardial infarction","author":"Hou","year":"2015","journal-title":"Stem Cell Rev"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0350","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","article-title":"Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies","volume":"71","author":"Hu-Lowe","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0355","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1523-1755.2004.00779.x","article-title":"Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction","volume":"66","author":"Inazaki","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0360","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.62.1.65","article-title":"SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7","volume":"62","author":"Inman","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0365","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1523-1755.1999.00275.x","article-title":"Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis","volume":"55","author":"Isaka","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0370","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1172\/JCI116874","article-title":"Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney","volume":"92","author":"Isaka","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0375","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI0215518","article-title":"Evidence that fibroblasts derive from epithelium during tissue fibrosis","volume":"110","author":"Iwano","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4111\/kju.2012.53.1.44","article-title":"Activin receptor-like kinase 5 inhibitor attenuates fibrosis in fibroblasts derived from Peyronie's plaque","volume":"53","author":"Jang","year":"2012","journal-title":"Kor. J.Urol."},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0385","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ajpath.2010.12.010","article-title":"BMP-6 emerges as a potential major regulator of fibrosis in the kidney","volume":"178","author":"Jenkins","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0390","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.ajpath.2014.01.026","article-title":"Inhibitory effects of PPARgamma ligands on TGF-beta1-induced corneal myofibroblast transformation","volume":"184","author":"Jeon","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0395","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2220\/biomedres.34.309","article-title":"Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways","volume":"34","author":"Ji","year":"2013","journal-title":"Biomed Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0400","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0405","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/mol.105.017483","article-title":"Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression","volume":"69","author":"Jinnin","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0410","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial\u2013mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0415","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/art.24761","article-title":"Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis","volume":"60","author":"Kapoor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0420","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.111.080002","article-title":"Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure","volume":"125","author":"Kapur","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/labinvest.2008.104","article-title":"PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta","volume":"89","author":"Kawai","year":"2009","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0430","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.ph.57.030195.001431","article-title":"Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?","volume":"57","author":"Ketteler","year":"1995","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0435","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00467-013-2430-y","article-title":"Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease","volume":"29","author":"Kida","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0440","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/00498250701871121","article-title":"Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor","volume":"38","author":"Kim","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0445","first-page":"991","article-title":"Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease","volume":"74","author":"Kopp","year":"1996","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0450","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cbi.2015.01.013","article-title":"Camel milk attenuates the biochemical and morphological features of diabetic nephropathy: inhibition of Smad1 and collagen type IV synthesis","volume":"229","author":"Korish","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0455","doi-asserted-by":"crossref","DOI":"10.1007\/s40139-013-0026-7","article-title":"Matrix producing cells in chronic kidney disease: origin, regulation, and activation","volume":"1","author":"Kramann","year":"2013","journal-title":"Curr Pathobiol Rep"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0460","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1172\/JCI44595","article-title":"Epithelial\u2013mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?","volume":"121","author":"Kriz","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0465","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1073\/pnas.90.2.770","article-title":"Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death","volume":"90","author":"Kulkarni","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0470","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/onc.2013.386","article-title":"Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling","volume":"33","author":"Kumar","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0475","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urology.2005.09.028","article-title":"Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy","volume":"67","author":"Kuwabara","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0480","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.27307","article-title":"Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis","volume":"62","author":"Lagares","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/mol.62.1.58","article-title":"Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542","volume":"62","author":"Laping","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0490","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nm.3218","article-title":"Origin and function of myofibroblasts in kidney fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0495","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.immunol.16.1.137","article-title":"Regulation of immune responses by TGF-beta","volume":"16","author":"Letterio","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0510","doi-asserted-by":"crossref","first-page":"593956","DOI":"10.1155\/2014\/593956","article-title":"MicroRNAs in diabetic kidney disease","volume":"2014","author":"Li","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0505","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/cas.12093","article-title":"Bone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells","volume":"104","author":"Li","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0500","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.2337\/db09-1631","article-title":"Blockade of endothelial\u2013mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy","volume":"59","author":"Li","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0515","doi-asserted-by":"crossref","first-page":"e58848","DOI":"10.1371\/journal.pone.0058848","article-title":"Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0525","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2015.01.004","article-title":"Role of eukaryotic translation initiation factor 3a in bleomycin-induced pulmonary fibrosis","volume":"749","author":"Li","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0520","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2015.00114","article-title":"Role of bone morphogenetic protein-7 in renal fibrosis","volume":"6","author":"Li","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0530","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nm1217","article-title":"Kielin\/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease","volume":"11","author":"Lin","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0535","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1124\/jpet.105.097667","article-title":"Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network","volume":"317","author":"Lipecka","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2015.10.003_bb0540","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/ndt\/gft267","article-title":"Transforming growth factor-beta and the progression of renal disease","volume":"29","author":"Loeffler","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0545","doi-asserted-by":"crossref","first-page":"36202","DOI":"10.1074\/jbc.M113.498634","article-title":"MicroRNA-22 is a master regulator of bone morphogenetic protein-7\/6 homeostasis in the kidney","volume":"288","author":"Long","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0550","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00441-011-1275-6","article-title":"Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects","volume":"347","author":"Lopez-Hernandez","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0555","doi-asserted-by":"crossref","first-page":"H959","DOI":"10.1152\/ajpheart.01251.2009","article-title":"The physiological role of endoglin in the cardiovascular system","volume":"299","author":"Lopez-Novoa","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0560","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrneph.2011.26","article-title":"MicroRNAs as mediators and therapeutic targets in chronic kidney disease","volume":"7","author":"Lorenzen","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0570","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.2001.0590051899.x","article-title":"Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats","volume":"59","author":"Ma","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0565","doi-asserted-by":"crossref","first-page":"F1263","DOI":"10.1152\/ajprenal.00211.2014","article-title":"ASK1\/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney","volume":"307","author":"Ma","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0575","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.juro.2011.01.034","article-title":"The BMP-7-Smad1\/5\/8 pathway promotes kidney repair after obstruction induced renal injury","volume":"185","author":"Manson","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0580","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.yexcr.2006.03.008","article-title":"Involvement of H- and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis","volume":"312","author":"Martinez-Salgado","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0585","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00018-007-7260-2","article-title":"Involvement of small Ras GTPases and their effectors in chronic renal disease","volume":"65","author":"Martinez-Salgado","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0590","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35043051","article-title":"How cells read TGF-beta signals","volume":"1","author":"Massague","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0595","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","article-title":"TGFbeta signaling in growth control, cancer, and heritable disorders","volume":"103","author":"Massague","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0600","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/labinvest.3700400","article-title":"Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy","volume":"86","author":"Matsubara","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0605","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1073\/pnas.090020497","article-title":"Xenopus kielin: a dorsalizing factor containing multiple chordin-type repeats secreted from the embryonic midline","volume":"97","author":"Matsui","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0610","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural\u2013functional relationships in diabetic nephropathy","volume":"74","author":"Mauer","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0615","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1167\/iovs.02-0978","article-title":"Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery","volume":"44","author":"Mead","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0620","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/CS20120252","article-title":"Role of the TGF-beta\/BMP-7\/Smad pathways in renal diseases","volume":"124","author":"Meng","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0625","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1681\/ASN.2009121244","article-title":"Smad2 protects against TGF-beta\/Smad3-mediated renal fibrosis","volume":"21","author":"Meng","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0630","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/path.3976","article-title":"Diverse roles of TGF-beta receptor II in renal fibrosis and inflammation in vivo and in vitro","volume":"227","author":"Meng","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0635","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ki.2011.327","article-title":"Disruption of Smad4 impairs TGF-beta\/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro","volume":"81","author":"Meng","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0640","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphys.2015.00082","article-title":"TGF-beta\/Smad signaling in renal fibrosis","volume":"6","author":"Meng","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0645","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cellsig.2010.12.002","article-title":"Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling","volume":"23","author":"Meurer","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0650","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/labinvest.3700445","article-title":"Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy","volume":"86","author":"Mima","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0655","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1535-7163.MCT-09-0650","article-title":"ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth","volume":"9","author":"Mitchell","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2015.10.003_bb0660","first-page":"S79","article-title":"Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0665","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/sj.ki.5001775","article-title":"IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy","volume":"70","author":"Moon","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0670","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/jcp.22690","article-title":"Endoglin promotes TGF-beta\/Smad1 signaling in scleroderma fibroblasts","volume":"226","author":"Morris","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0675","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1242\/jcs.02554","article-title":"Non-Smad TGF-beta signals","volume":"118","author":"Moustakas","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0680","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cytogfr.2013.08.002","article-title":"ALK1-Smad1\/5 signaling pathway in fibrosis development: friend or foe?","volume":"24","author":"Munoz-Felix","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0685","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ki.2013.292","article-title":"Heterozygous disruption of activin receptor-like kinase 1 is associated with increased renal fibrosis in a mouse model of obstructive nephropathy","volume":"85","author":"Munoz-Felix","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0690","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1017\/erm.2014.20","article-title":"The role of endoglin in kidney fibrosis","volume":"16","author":"Munoz-Felix","year":"2014","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0695","doi-asserted-by":"crossref","first-page":"e21911","DOI":"10.1371\/journal.pone.0021911","article-title":"CCN2 is required for the TGF-beta induced activation of Smad1-Erk1\/2 signaling network","volume":"6","author":"Nakerakanti","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","article-title":"Tubulointerstitial changes as a major determinant in the progression of renal damage","volume":"20","author":"Nath","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0705","doi-asserted-by":"crossref","first-page":"e50920","DOI":"10.1371\/journal.pone.0050920","article-title":"Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies","volume":"7","author":"Nolan-Stevaux","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0710","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/db05-1285","article-title":"Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms","volume":"55","author":"Okada","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0715","doi-asserted-by":"crossref","first-page":"e110365","DOI":"10.1371\/journal.pone.0110365","article-title":"L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction","volume":"9","author":"Oujo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0720","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/art.23698","article-title":"Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate","volume":"58","author":"Pannu","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0725","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1074\/jbc.M611742200","article-title":"Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1\/2 pathways","volume":"282","author":"Pannu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0730","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00018-014-1798-6","article-title":"EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-beta\/Smad and ROS signaling","volume":"72","author":"Park","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0735","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1073\/pnas.111145798","article-title":"Molecular mechanisms of translation initiation in eukaryotes","volume":"98","author":"Pestova","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0740","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.ki.5002717","article-title":"Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis","volume":"73","author":"Petersen","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0745","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbadis.2009.06.004","article-title":"TGF-beta and fibrosis in different organs \u2014 molecular pathway imprints","volume":"1792","author":"Pohlers","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0750","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.bjp.0703578","article-title":"Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats","volume":"131","author":"Punithavathi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0755","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2008090931","article-title":"Pirfenidone is renoprotective in diabetic kidney disease","volume":"20","author":"RamachandraRao","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0760","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12986-015-0004-7","article-title":"Inhibition of TGF-beta by a novel PPAR-gamma agonist, chrysin, salvages beta-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism","volume":"12","author":"Rani","year":"2015","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0765","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0770","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/bbrc.2001.4526","article-title":"Endoglin expression in human and rat mesangial cells and its upregulation by TGF-beta1","volume":"282","author":"Rodriguez-Barbero","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0775","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0014-5793(02)02337-2","article-title":"Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts","volume":"513","author":"Rodriguez-Barbero","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0780","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.HYP.0000037429.73954.27","article-title":"Endoglin upregulation during experimental renal interstitial fibrosis in mice","volume":"40","author":"Rodriguez-Pena","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0790","doi-asserted-by":"crossref","first-page":"124902","DOI":"10.1155\/2014\/124902","article-title":"Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy","volume":"2014","author":"Rodriguez-Pena","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0795","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ki.2008.160","article-title":"Activation of Erk1\/2 and Akt following unilateral ureteral obstruction","volume":"74","author":"Rodriguez-Pena","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2015.10.003_bb0785","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ndt\/16.suppl_1.34","article-title":"Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction","volume":"16","author":"Rodriguez-Pena","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0800","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5414\/CN107371","article-title":"The role played by perivascular cells in kidney interstitial injury","volume":"77","author":"Rojas","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0805","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-12-0098","article-title":"A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer","volume":"18","author":"Rosen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0810","first-page":"55","article-title":"Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease","volume":"5","author":"Roy-Chaudhury","year":"1997","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0815","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01216.x","article-title":"IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease","volume":"6","author":"Ryu","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0820","doi-asserted-by":"crossref","first-page":"43799","DOI":"10.1074\/jbc.M207160200","article-title":"Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways","volume":"277","author":"Sanchez-Elsner","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0825","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1073\/pnas.92.7.2572","article-title":"Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions","volume":"92","author":"Sanderson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/CS20110086","article-title":"TGF-beta\/TGF-beta receptor system and its role in physiological and pathological conditions","volume":"121","author":"Santibanez","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0835","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1172\/JCI200319270","article-title":"Targeted disruption of TGF-beta1\/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction","volume":"112","author":"Sato","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0840","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0046-8177(70)80061-2","article-title":"Structural\u2013functional correlations in renal disease. II. The correlations","volume":"1","author":"Schainuck","year":"1970","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0845","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.radonc.2011.05.061","article-title":"ALK1 heterozygosity delays development of late normal tissue damage in the irradiated mouse kidney","volume":"99","author":"Scharpfenecker","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0850","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.radonc.2013.06.016","article-title":"Endoglin haploinsufficiency attenuates radiation-induced deterioration of kidney function in mice","volume":"108","author":"Scharpfenecker","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0855","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.radonc.2012.08.021","article-title":"The TGF-beta co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney","volume":"105","author":"Scharpfenecker","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0860","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.radonc.2009.06.013","article-title":"Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys","volume":"92","author":"Scharpfenecker","year":"2009","journal-title":"Radiother Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2015.10.003_bb0865","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1681\/ASN.2004110970","article-title":"Pathogenetic mechanisms of diabetic nephropathy","volume":"16","author":"Schena","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0870","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ndt\/5.10.889","article-title":"Number of interstitial capillary cross-sections assessed by monoclonal antibodies: relation to interstitial damage","volume":"5","author":"Seron","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0875","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0880","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2337\/diab.45.4.522","article-title":"Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice","volume":"45","author":"Sharma","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0885","first-page":"116","article-title":"The transforming growth factor-beta system and the kidney","volume":"13","author":"Sharma","year":"1993","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0890","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ki.2013.82","article-title":"Inhibition of TGF-beta1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis","volume":"84","author":"Shen","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0895","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ejca.2012.10.016","article-title":"Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors","volume":"49","author":"Simonelli","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0900","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1681\/ASN.2012070759","article-title":"Kielin\/chordin-like protein attenuates both acute and chronic renal injury","volume":"24","author":"Soofi","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0905","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1681\/ASN.2006050420","article-title":"Renal fibroblasts and myofibroblasts in chronic kidney disease","volume":"17","author":"Strutz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0910","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nm.2629","article-title":"Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis","volume":"18","author":"Sugimoto","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0915","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0024-3205(98)00166-0","article-title":"Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction","volume":"62","author":"Sutaria","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0920","article-title":"Projecting the United States ESRD population: issues regarding treatment of patients with ESRD","volume":"S3\u20137","author":"Szczech","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0925","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2014.05.015","article-title":"Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis","volume":"737","author":"Takakura","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0930","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ki.1994.68","article-title":"TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy","volume":"45","author":"Tamaki","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0935","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2014.14","article-title":"Potential approaches to reverse or repair renal fibrosis","volume":"10","author":"Tampe","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0940","doi-asserted-by":"crossref","first-page":"H1415","DOI":"10.1152\/ajpheart.01048.2009","article-title":"Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction","volume":"298","author":"Tan","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0945","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2014.03.045","article-title":"R-268712, an orally active transforming growth factor-beta type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model","volume":"734","author":"Terashima","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"Pt B","key":"10.1016\/j.pharmthera.2015.10.003_bb0950","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-364935-5.50009-2","article-title":"Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits","volume":"34","author":"Terrell","year":"1993","journal-title":"Int Rev Exp Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0955","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00395-014-0443-8","article-title":"Cardiospheres reverse adverse remodeling in chronic rat myocardial infarction: roles of soluble endoglin and Tgf-beta signaling","volume":"109","author":"Tseliou","year":"2014","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0960","author":"USRDS"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0965","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1242\/jcs.023283","article-title":"L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts","volume":"121","author":"Velasco","year":"2008","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0970","first-page":"1791","article-title":"Circulating microRNAs as biomarkers in health and disease","volume":"6","author":"Velu","year":"2012","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0975","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbadis.2012.11.007","article-title":"BAMBI (BMP and activin membrane-bound inhibitor) protects the murine heart from pressure-overload biomechanical stress by restraining TGF-beta signaling","volume":"1832","author":"Villar","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0980","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/db10-0892","article-title":"miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression","volume":"60","author":"Wang","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0990","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1797.2005.00334.x","article-title":"Transforming growth factor-beta and Smad signalling in kidney diseases","volume":"10","author":"Wang","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0985","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1440-1681.12249","article-title":"Role of microRNA machinery in kidney fibrosis","volume":"41","author":"Wang","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb0995","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1158\/0008-5472.CAN-10-1722","article-title":"Cancer exosomes trigger fibroblast to myofibroblast differentiation","volume":"70","author":"Webber","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1000","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1874312901206010103","article-title":"Regulation of matrix remodeling by peroxisome proliferator-activated receptor-gamma: a novel link between metabolism and fibrogenesis","volume":"6","author":"Wei","year":"2012","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/BOR.0b013e32833de1a7","article-title":"Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis","volume":"22","author":"Wei","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1015","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.2741\/3583","article-title":"BMP-7 as antagonist of organ fibrosis","volume":"14","author":"Weiskirchen","year":"2009","journal-title":"Front Biosci"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1020","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1681\/ASN.V1191667","article-title":"Type 2 diabetic patients with nephropathy show structural\u2013functional relationships that are similar to type 1 disease","volume":"11","author":"White","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/027298902320556118","article-title":"Health economic evaluations: the special case of end-stage renal disease treatment","volume":"22","author":"Winkelmayer","year":"2002","journal-title":"Med Decis Making"},{"issue":"2011","key":"10.1016\/j.pharmthera.2015.10.003_bb1030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/kisup.2014.15","article-title":"Biomarkers in kidney fibrosis: are they useful?","volume":"4","author":"Wong","year":"2014","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1035","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1681\/ASN.V12122753","article-title":"Forecast of the number of patients with end-stage renal disease in the United States to the year 2010","volume":"12","author":"Xue","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1045","doi-asserted-by":"crossref","first-page":"30097","DOI":"10.1074\/jbc.M109.049304","article-title":"Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling","volume":"284","author":"Yan","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1040","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/aps.2009.56","article-title":"BMP6 reverses TGF-beta1-induced changes in HK-2 cells: implications for the treatment of renal fibrosis","volume":"30","author":"Yan","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/CS20070462","article-title":"Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential","volume":"116","author":"Yang","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1472-6882-12-156","article-title":"Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats","volume":"12","author":"Yao","year":"2012","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/nm888","article-title":"BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury","volume":"9","author":"Zeisberg","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1065","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1681\/ASN.2010080793","article-title":"Mechanisms of tubulointerstitial fibrosis","volume":"21","author":"Zeisberg","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-beta signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/mt.2014.25","article-title":"miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta\/Smad3 signaling","volume":"22","author":"Zhang","year":"2014","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.pharmthera.2015.10.003_bb1080","first-page":"8983","article-title":"Knockdown of elF3a inhibits collagen synthesis in renal fibroblasts via inhibition of transforming growth factor-\u03b21\/Smad signaling pathway","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1085","doi-asserted-by":"crossref","first-page":"F639","DOI":"10.1152\/ajprenal.00189.2001","article-title":"Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation","volume":"282","author":"Zheng","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00125-012-2804-x","article-title":"miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes","volume":"56","author":"Zhong","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2015.10.003_bb1095","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1073\/pnas.120055097","article-title":"Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db\/db diabetic mice","volume":"97","author":"Ziyadeh","year":"2000","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:53:18Z","timestamp":1759009998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":219,"alternative-id":["S0163725815001849"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.10.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TGF-\u03b2\/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25years of trials and tribulations?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}